Exhibit 99.1 Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights • Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 • Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments • Strong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., May 9, 2024 -- Nkarta, Inc. (Nasdaq: NKTX), a clinic ...